26 . April , 2018 - Thursday
Check todays hot topics or new products

Find a Drug: Advanced

Please Sign in or Register

All about: Abacavir Sulfate/Lamivudine

Big Image Pronouncation: (ab-ah-KAV-ear SULL-fate/la-MIH-view-deen)
Class: Nucleoside analog reverse transcriptase inhibitor combination

Trade Names:
Epzicom
- Tablets 600 mg abacavir (as sulfate) and 300 mg lamivudine

Mechanism of Action

Pharmacology

Inhibits replication of HIV by incorporation into HIV DNA and producing incomplete, nonfunctional DNA.

Indications and Usage

Treatment of HIV-1 infection in combination with other antiretroviral agents.

Contraindications

Abacavir has been associated with fatal hypersensitivity reactions and should not be restarted following a hypersensitivity reaction to abacavir; hypersensitivity to any component of product; hepatic function impairment.

Dosage and Administration

Adults

PO 1 tablet daily (abacavir sulfate 600 mg and lamivudine 300 mg), in combination with other antiretroviral agents.

Storage/Stability

Store tablets at controlled room temperature (59° to 86°F).

Drug Interactions

Trimethoprim/Sulfamethoxazole

Lamivudine serum levels may be elevated, increasing the pharmacologic and adverse effects.

Zidovudine

Lamivudine and zidovudine may inhibit the intracellular phosphorylation of each other.

Laboratory Test Interactions

None well documented.

Adverse Reactions

The following adverse reactions were reported during postapproval use of abacavir and lamivudine. Adverse reactions occurring with administration of either abacavir or lamivudine can be found listed in their respective monographs.

CNS

Paresthesia; peripheral neuropathy; seizures.

Dermatologic

Alopecia; erythema multiforme; Stevens-Johnson syndrome.

GI

Stomatitis.

Hematologic-Lymphatic

Aplastic anemia; anemia (including pure red cell aplasia and severe anemia progressing with therapy); lymphadenopathy; splenomegaly.

Hepatic

Hepatic steatosis; posttreatment exacerbation of hepatitis B.

Metabolic

Hyperglycemia; lactic acidosis.

Musculoskeletal

Muscle weakness; CPK elevation; rhabdomyolysis.

Respiratory

Abnormal breath sounds/wheezing.

Miscellaneous

Sensitivity reactions (including anaphylaxis); redistribution/accumulation of body fat; weakness.

Precautions

Warnings

Serious and sometimes fatal hypersensitivity reactions have been associated with abacavir. The hypersensitivity reaction is a multi-organ syndrome usually characterized by signs or symptoms in 2 or more of the following: 1) fever, 2) rash, 3) GI (eg, nausea, vomiting), 4) constitutional (eg, malaise, fatigue), and 5) respiratory (eg, cough). Permanently discontinue if hypersensitivity reaction occurs. Do not restart abacavir following a hypersensitivity reaction. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, may occur. Severe acute exacerbation of hepatitis B has been reported in patient co-infected with hepatitis B virus (HBV) and HIV and who have discontinued lamivudine. Closely monitor hepatic function for at least several months after discontinuation of abacavir/lamivudine in patients who are co-infected with HIV and HBV.


Monitor

Discontinuation

Ensure hepatic function is closely monitored for at least several months following discontinuation of abacavir/lamivudine in patient who is co-infected with HBV and HIV. Ensure anti-hepatitis B therapy has been considered.

Lactic acidosis

Monitor patient for signs of lactic acidosis. If patient develops profound weakness or tiredness, unexpected stomach discomfort, cold feeling, dizziness, or lightheadedness, slow or irregular heartbeat, withhold drug and notify health care provider.


Pregnancy

Category C .

Lactation

Undetermined. HIV-infected mothers should not breast-feed their infants.

Children

Safety and efficacy not established.

Renal Function

Because this is a fixed-dose tablet, do not use for patients requiring dosage adjustment (eg, Ccr less than 50 mL/min).

Hepatic Function

Because this is a fixed-dose tablet and the dosage of the individual components cannot be altered, it is contraindicated in patients with hepatic function impairment.

Abacavir

Do not administer to patient who has previous suspected or documented hypersensitivity reaction to abacavir.

Antiretroviral agents

Must be used in combination with other antiretroviral agents from different pharmacologic classes (not with other nucleoside/nucleotide reverse transcriptase inhibitors).

Fat redistribution

Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, and cushingoid appearance have been observed in patients receiving antiretroviral therapy.

Patient Information

  • Advise patient to review Medication Guide before starting therapy and with each refill of the medication.
  • Advise patient to review, and carry with them at all times, the Warning Card summarizing the symptoms of abacavir hypersensitivity reaction.
  • Instruct patient to take exactly as prescribed and not to change the dose or discontinue therapy unless advised by health care provider.
  • Instruct patient to take 1 tablet once daily without regard to meals but to take with food if stomach upset occurs.
  • Instruct patient that if a dose is missed to take as soon as remembered and to take the next dose at the usual scheduled time.
  • Warn patient that this drug is not to be used by itself but is combined with other antiviral agents and to continue to take other HIV medications as prescribed by health care provider.
  • Instruct patient to discontinue use and notify health care provider immediately if a symptom from 2 or more of the following groups occurs: 1) fever; 2) rash; 3) nausea, vomiting, diarrhea, stomach pain; 4) generalized body discomfort, extreme tiredness, achiness; 5) sore throat, shortness of breath, cough.
  • Caution patient not to restart this medication, or any other abacavir-containing medication, if a hypersensitivity reaction to this medication has occurred. Explain to patient that restarting abacavir or an abacavir-containing product could cause a more serious, and possibly fatal, reaction.
  • Caution patient that if therapy is interrupted for a few days for reasons other than a hypersensitivity reaction (eg, interruption in drug supply) and is then restarted that there is a risk of experiencing a serious or fatal hypersensitivity reaction. Advise patient to talk with health care provider before restarting the medication. Advise patient that if health care provider tells them to take the medication again to start taking it when they are around medical help or people who could call a doctor if necessary.
  • Caution patient that medication can cause a rare but serious condition called lactic acidosis with liver enlargement and that persistent nausea and tiredness may be symptoms of this condition. Instruct patient to inform health care provider if these symptoms develop.
  • Caution patient who has concurrent infection with HBV that hepatitis may worsen if abacavir/lamivudine is stopped and that liver function should be closely followed for several months after stopping abacavir/lamivudine. Advise patient anti-hepatitis B virus medications may be needed.
  • Advise patient that medication may cause changes in body fat distribution (eg, increased amount of fat in upper back and neck, breasts, and around the back, chest, and stomach area; or loss of fat from arms, legs, and face) and that the cause and long-term health effects of these changes is not known at this time. Advise patient to report changes in body fat distribution to health care provider.
  • Inform patient that drug does not completely eliminate HIV virus and therefore does not reduce the risk of transmitting HIV to others through sexual contact or blood contamination. Instruct patient that appropriate precautions must still be followed.
  • Advise patient that drug is not a cure for HIV infection and illnesses associated with HIV infection, including opportunistic infections, may continue to be acquired. Patients should remain under a health care provider's care.
  • Instruct mother not to breast-feed her infant because of risk of transmitting HIV virus to the infant and the potential for serious adverse effects from medication transmitted to her infant through breast milk.

Recent Drug Updates at DrugIndexOnline:





Amphocin Amphocin
Some commonly used brand names are: In the U.S.— Amphocin Fungizone Intravenous In Canada— Fungizone Intravenous Generic name product may be available in the U.S. Category Antifungal, systemic antiprotozoal Description Amphotericin B (am-foe-TER-i-sin Bee) is an antifunga more...

Aspirin Caplets Aspirin Caplets
Some commonly used brand names are: In the U.S.— Acuprin 81 1 Amigesic 8 Anacin Caplets 2 Anacin Maximum Strength 2 Anacin Tablets 2 Anaflex 750 8 Arthritis Pain Ascriptin 3 Arthritis Pain Formula 3 Arthritis Strength Bufferin 3 Arthropan 5 Aspergum 1 Aspirin Regimen Bayer Adult Low Dose more...

Ceftibuten Ceftibuten
Pronouncation: (seff-TIE-byoo-ten) Class: Antibiotic, Cephalosporin Trade Names: Cedax - Capsules 400 mg - Powder for oral suspension 90 mg per 5 mL - Powder for oral suspension 180 mg per 5 mL Mechanism of Action Pharmacology Inhibits mucopeptide synthesis in bacterial cell wall. Pharmacokinetics more...

gotu kola gotu kola
Generic Name: gotu kola (GO two KOE lah) Brand Names: What is gotu kola? The use of gotu kola in cultural and traditional settings may differ from concepts accepted by current Western medicine. When considering the use of herbal supplements, consultation with a primary health care profe more...

Menthyl Anthranilate, Octocrylene, and Octyl Methoxycinnamate Topical Menthyl Anthranilate, Octocrylene, and Octyl Methoxycinnamate Topical
Some commonly used brand names are: In the U.S.— A-Fil 33 Aquaderm Sunscreen Moisturizer 49 Aquaray Sunscreen 42 Bain de Soleil All Day For Kids 38 Bain de Soleil All Day Sunfilter 39 Bain de Soleil Mega Tan 34 Bain de Soleil Orange Gelee 41 Bain de Soleil Sand Buster 41 Bain de Soleil SP more...

Norvir SEC Norvir SEC
Some commonly used brand names are: In the U.S.— Norvir In Canada— Norvir Norvir SEC Category Antiviral, systemic Description Ritonavir (rit-ON-uh-veer) is used, alone or in combination with other medicines, in the treatment of the infection caused by the human immunodefi more...

Nystatin and Triamcinolone Ointment Nystatin and Triamcinolone Ointment
Generic Name: Nystatin and Triamcinolone acetonide Dosage Form: Ointment For Dermatologic Use Only Not For Ophthalmic Use Rx only Nystatin and Triamcinolone Description Nystatin and Triamcinolone acetonide ointment, USP for dermatologic use contains the antifungal agent nystatin and the syntheti more...

Phenergan Suppositories Phenergan Suppositories
Generic Name: Promethazine Suppositories (proe-METH-a-zeen) Brand Name: Phenergan Phenergan Suppositories should not be used in children younger than 2 years old. Potentially fatal side effects (eg, difficult or slowed breathing, drowsiness leading to coma) may occur in this age group when takin more...